Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2013 Feb;33(2):553-7.

Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.

Author information

1
267 Experimental Urology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands. J.Schalken@uro.umcn.nl

Abstract

BACKGROUND:

Prostate Cancer Gene-3 (PCA3) is highly prostate cancer (PCa)-specific and its application holds promise in identifying men with PCa.

AIM:

To determine whether the PCA3 score can be used relative to PCa clinical variables to predict biopsy outcome.

PATIENTS AND METHODS:

PCA3 scores were assessed in a group of 80 patients using the Progensa assay (Gen-Probe, San Diego, CA, USA). The logistic regression algorithm was used to combine PCA3 results with the established biopsy risk factors including: age, prostate-specific antigen (PSA), digital rectal examination (DRE) and prostate volume (Pvol).

RESULTS:

In univariate analyses, the Progensa PCA3 score outperformed all biopsy risk predictors. A logistic regression algorithm using: age, PCA3, PSA, DRE and Pvol increased the area under the Receiver Operating Characteristic (ROC) curve from 0.72 for PCA3-alone to 0.85.

CONCLUSION:

Combining PCA3 results with PCa risk factors provides significant improvements over the use of PCA3- or PSA-alone in predicting the probability of a positive prostate biopsy.

PMID:
23393348
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center